Disruption
The top ten pharma companies best positioned to weather future industry disruption
The proportion of pharmaceutical companies hiring for cloud related positions rose to a year-high in August 2021, with 42.7% of the companies included in our analysis recruiting for at least one such position.
Pfizer leads in a US-heavy list of top pharma companies based on extensive research by GlobalData.
Powered by
Pfizer is the pharmaceutical company best positioned to take advantage of future drug development disruption in the industry, according to GlobalData analysts.
The USA-based firm comes top of the list in a ranking of overall leadership in the themes that matter most among drug development companies.
These themes, which can be defined as any issues that keep CEOs awake at night, describe technological, macroeconomic and industry-specific challenges that companies are currently facing, as well as the opportunities they create. GlobalData's Thematic Research ecosystem identifies and tracks these challenges, and how they create the long-term winners and losers of the industry.
Pfizer scored highly in several areas, particularly when it comes to Precision and Personalized Medicine, Rare Diseases, Biosimilars, NanoTech, Genomics, Strategic Partnerships and Artificial Intelligence, where it received top marks of five out of five.
Pfizer received scores of four for Immuno-Oncology and Regenerative Medicine and three for Microbiome performances.
These scores represent GlobalData analysts' assessments of the competitiveness of each company regarding a particular theme. They are then weighted based on their importance and used to create the final industry ranking.
Pfizer is followed in our ranking by Novartis, Catalent and Merck & Co.
The interactive graphic below allows you to compare company ratings across the 10 themes in question. The higher up a company is on the list, the better positioned it is to weather disruption in the future, while the companies at the bottom are more vulnerable to disruptive threats.
Our analysis reveals that companies from USA are some of the best-prepared players in the drug development game. Companies from India and China also performed well.
These scores are based on overall technology, macroeconomic and sector-specific leadership in 10 of the key themes that matter most to the industry and are generated by GlobalData analysts' assessments.
This article is based on GlobalData research figures as of 15 August, 2022. For more up to date figures, check the GlobalData website.
